You are here

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Obesity

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Diabetes mellitus (type 1 or type 2) Heart failure Eating disorders Psychiatric disorders
History of suicide attempt History of pancreatitis

NCT01472848
Pfizer
Withdrawn
A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Obesity
NCT00367783
All Genders
18+
Years
Multiple Sites
Morbid Obesity, Metabolic Disease
NCT00283374
All Genders
18+
Years
Multiple Sites
A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
A Randomized, Double-Blind, Outpatient, Placebo-Controlled, Dose Titration Study Of Gastrointestinal Tolerability Of Pf 05212389 (Oap-189) In Obese Subjects
This study examines whether a gradual increase of dose improves the gastrointestinal tolerability (nausea and vomiting) of PF05212389
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Obesity
  • Drug: PF 05212389 or placebo
    QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
  • Drug: PF 05212389 or placebo
    QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
  • Experimental: Cohort 1
    Intervention: Drug: PF 05212389 or placebo
  • Experimental: Cohort 2
    Intervention: Drug: PF 05212389 or placebo
  • Experimental: Cohort 3
    Intervention: Drug: PF 05212389 or placebo
  • Experimental: Cohort 4
    Intervention: Drug: PF 05212389 or placebo
  • Experimental: Cohort 5
    Intervention: Drug: PF 05212389 or placebo
  • Active Comparator: Cohort 6
    Intervention: Drug: PF 05212389 or placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
August 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Obesity

Exclusion Criteria:

Diabetes mellitus (type 1 or type 2) Heart failure Eating disorders Psychiatric disorders History of suicide attempt History of pancreatitis

Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01472848
B2201010
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now